Prostate cancer is a health issue that impacts individuals worldwide, and choosing the best treatment can be difficult, given ...

Advanced prostate cancer is cancer that has spread beyond the prostate to distant parts of the body. It is also called ...

Dalpiciclib is under clinical development by Jiangsu Hengrui Medicine and currently in Phase III for Hormone-Sensitive Prostate Cancer.

This article provides an overview of developments in advanced prostate cancer and considers how the available options for lengthening survival for men with mCRPC may be sequenced.

According to GlobalData, Phase II drugs for Hormone-Sensitive Prostate Cancer have a 74% phase transition success rate (PTSR) indication benchmark for progressing into ... is for the treatment of ...

Treating Prostate ... cancer without accompanying hormone therapy for men who have mutations in genes such as BRCA2, according to ... Precision Therapy for Metastatic Prostate Cancer Improves ...

Prostate cancer treatment has ... techniques like radioligand therapy offer new hope for patients enabling better quality of life and improved survival rates. Discussing these options with a ...

Prostate cancer ranks among the most common health challenges men face worldwide. While medical advances continue to improve treatment outcomes, the e ...

Prostate cancer is the second most common cancer found in men. (Skin cancer is the most common cancer.) More than 230,000 new cases will be diagnosed this year. Chances are you know someone who has ...

This therapy is also called androgen deprivation therapy (ADT). Testosterone, an important male sex hormone, is the main fuel for prostate cancer cells, so reducing its levels may slow the growth of ...

Background and objectives: The standard of care for patients with metastatic hormone-sensitive prostate cancer (mHSPC) includes androgen deprivation therapy (ADT), novel ... the 5- and 10-year CSS ...